Drug Search Results
More Filters [+]

Carmoterol

Alternative Names: carmoterol
Latest Update: 2017-04-11
Latest Update Note: Clinical Trial Update

Product Description

For Chronic Obstructive Pulmonary Disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00640484)

Mechanisms of Action: ADRB2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Turkey

Approved Indications: None

Known Adverse Events: None

Company: Chiesi
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Carmoterol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Asthma|Chronic Obstructive Pulmonary Disease

Phase 1: Chronic Obstructive Pulmonary Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OHRQoL in down syndrome

N/A

Not yet recruiting

Cystic Fibrosis|Asthma

2018-06-30

2009-013759-32

P2

Completed

Asthma

2010-06-23

2008-001773-15

P2

Completed

Asthma

2009-01-06

CT14

P1

Completed

Chronic Obstructive Pulmonary Disease

2008-12-01

Recent News Events

Date

Type

Title